BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy
BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease
Ness Ziona, Israel – Nov. 3, 2020 – BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the first subject has been dosed in a Phase 1a study of BX002, a phage therapy candidate for the treatment of inflammatory bowel disease (IBD). The first-in-human study is designed to evaluate the safety, pharmacokinetics, and ability of orally-administered BX002 to deliver viable phage to the gut. The therapy targets strains of Klebsiella pneumoniae that cause strong TH1 immune stimulation and colitis in mouse models of disease and are known to be present at a higher prevalence and abundance in IBD patients relative to healthy individuals.